0.76
0.76 (0%)
As of Apr 17, 2025
Cue Biopharma, Inc. [CUE]
Source:
Company Overview
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing precision immunotherapies to treat cancer and autoimmune diseases.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (617) 949-2680 |
| Industry | manufacturing |
| CEO | Daniel R. Passeri |
| Website | www.cuebiopharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $9.3 |
| Operating Profit | $-41.5 |
| Net Income | $-40.7 |
| Net Cash | $-26.1 |
Profit Ratios
| Gross Margin | $9.3 |
| Operating Margin | -446.9 |
| Profit as % of Revenues | -22.8% |
| Profit as % of Assets | -86.8% |
| Profit as % of Stockholder Equity | -232.4% |
Management Effectiveness
| Return on Equity | -232.4% |
| Return on Assets | -126.4% |
| Turnover Ratio | 19.8% |
| EBITA | $-41.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $32.2 |
| Total Liabilities | $14.7 |
| Operating Cash Flow | $-36.3 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $10.2 |
